EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile

« Back to Dashboard

When do Emtricitabine, Rilpivirine And Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Emtricitabine, Rilpivirine And Tenofovir Disoproxil Fumarate launch?

Emtricitabine, Rilpivirine And Tenofovir Disoproxil Fumarate is a drug marketed by Laurus and Mylan and is included in two NDAs.

The generic ingredient in EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate. Three suppliers are listed for this compound. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate profile page.

Summary for EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Laurus	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	220232-001	Mar 4, 2026	AB	RX	No	No
Mylan	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	208452-001	May 20, 2025	AB	RX	No	No

EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE (TDF) Investment Fundamentals: Market Size, Patent/Exclusivity Risk, Litigation, and Generic/Biosimilar Entry Scenarios

Last updated: July 19, 2026

EMTRICITABINE, RILPIVIRINE and TENOFOVIR DISOPROXIL FUMARATE is a fixed-dose antiretroviral combination used in HIV treatment. Investment-grade diligence turns on (1) how much remaining revenue is tied to brand exclusivity versus generic substitution, (2) whether ongoing patent “orange book” coverage blocks ANDA entry for specific dosage forms/strengths, and (3) the extent of supply and price pressure from multiple authorized and non-authorized generic filers.

Core investment framing: the product’s fundamentals are typically dominated by global HIV procurement patterns and rapid generic adoption in TDF-based regimens. The key upside lever is whether any formulation, method-of-use, or combination-specific patents still restrict generic entry in priority markets. The key downside lever is that most TDF/emtricitabine and rilpivirine assets are already off-patent or approaching that state, leaving limited brand durability.

---

EMTRICITABINE RILPIVIRINE TENOFOVIR DISOPROXIL FUMARATE: What is the current commercial reality and price/volume pressure?

Featured snippet answer: Revenue is usually structurally pressured by generic competition because TDF and emtricitabine components have long-established generic entry routes and HIV payer formularies tend to favor lowest net cost after patent expiry.

How do HIV purchasing dynamics affect margins?

• HIV medicines in major markets are purchased through a mix of national formularies, PBM contracts, and large institutional procurement.
• After credible generic entry, net pricing commonly declines quickly due to tenders and formulary switches, especially where payers anchor to “therapeutic equivalents.”

What tends to drive unit growth or decline?

• Patient retention depends on regimen tolerability and virologic stability.
• Switch behavior is driven by guideline updates and patient-specific factors (drug-drug interactions, renal function for TDF, and tolerability for NNRTI class members).

Investment implication

• If brand revenue is still material, the investment case must show ongoing exclusivity in at least one major market or a non-generic-protected differentiation, such as a protected dosing instruction, formulation, or manufacturing method.

---

What patents protect EMTRICITABINE RILPIVIRINE and TENOFOVIR DISOPROXIL FUMARATE in the US, and how many are still active?

Featured snippet answer: Patent protection for combination ARVs usually includes multiple layers: composition-of-matter, formulation, and method-of-use claims. The number of still-active patents is determinative for how fast ANDA filers can enter and what label carve-outs remain.

Patent estate map investors track

1. Composition-of-matter patents (often for each active ingredient and key combination structures).
2. Formulation patents (fixed-dose tablets, stability and dissolution claims, and specific manufacturing states).
3. Method-of-use patents (dose regimens, patient selection, timing requirements).
4. Manufacturing process patents (granulation, mixing, coating, or crystallization steps relevant to tablets).

Where investors look for practical barriers

• Orange Book listings tied to the exact strength(s) and dosage form(s) for the marketed product.
• Whether remaining patents are listed under “drug substance,” “drug product,” or “method of use.”
• Whether claims are likely to survive an ANDA obviousness/novelty and 35 USC 101 landscape, and whether FDA approval can proceed with design-around.

Investment implication

• A portfolio dominated by old composition-of-matter claims that are already expired generally translates into limited exclusivity and high generic substitution risk.
• The highest-value remaining assets tend to be narrow but enforceable formulation or method-of-use claims that prevent generic labeling or require a non-infringing design-around.

---

When does EMTRICITABINE/RILPIVIRINE/TDF lose exclusivity, and what are the key timeline gates for ANDA entry?

Featured snippet answer: ANDA entry timing is governed by the latest relevant US patent expiration and by any exclusivity periods tied to the NDA/BLA record. The practical launch window is the earliest date a generic can legally market with a Paragraph IV certification and that the branded sponsor cannot block by injunction or loss of the relevant stay.

Key timeline gates to model

• Primary composition-of-matter expiration
• Secondary formulation/method-of-use expiration
• Regulatory exclusivities (if any apply to the NDA record)
• 30-month stay following a Paragraph IV ANDA notice
• Any litigation settlement or consent decree that changes the launch date

Investment implication

• For fixed-dose combination ARVs, the most investor-relevant question is not just “when patents expire,” but whether the remaining patents block FDA approval and Orange Book exclusivity in priority strengths.

---

What is the Orange Book status of EMTRICITABINE, RILPIVIRINE and TENOFOVIR DISOPROXIL FUMARATE?

Featured snippet answer: The Orange Book status determines whether ANDA filers can reference the product and whether they can carve out or certify around active listed patents.

How to use Orange Book listings for underwriting

• Identify the exact NDA number for the marketed fixed-dose product.
• Record each listed patent with:
  • Patent number
  • Patent expiration date
  • Patent type (drug substance, drug product, method of use)
  • FDA regulatory exclusivity (if listed)
• Map those listings against expected ANDA filing strategies by generic applicants.

Investment implication

• If Orange Book shows many patents with late expirations for the exact strength/dosage form, the risk shifts from “automatic generic entry” to “litigation-driven delayed entry.”
• If Orange Book shows few or early expirations, the risk shifts toward swift generic penetration after the legal barrier falls.

---

Which companies are challenging EMTRICITABINE/RILPIVIRINE/TDF patents with Paragraph IV ANDAs?

Featured snippet answer: Generic challengers typically include multiple ANDA filers targeting the same fixed-dose strength once Orange Book barriers allow certification.

How investors interpret challenger behavior

• High challenger counts can indicate low sponsor enforceability or early expectation of settlement.
• Repeat patterns across strengths suggest standardized legal strategies for the same patent family.

Investment implication

• The investment question becomes whether challengers are likely to (a) lose and face injunction, (b) settle with authorized launch dates, or (c) win quickly and drive pricing collapse.

---

What patent litigation affects EMTRICITABINE/RILPIVIRINE/TDF, and what are the outcomes investors should model?

Featured snippet answer: For combination HIV products, litigation usually determines launch timing via 30-month stays, injunctions, and settlement-triggered entry.

Litigation elements to model

• Whether the sponsor sought and obtained an injunction.
• Whether the case reached merits decisions or settled on negotiated dates.
• Whether settlements include:
  • Agreed design-around
  • Launch date
  • Royalty or pay-for-delay considerations
  • Supply or exclusivity agreements

Investment implication

• Settlements can create “predictable” generic entry timing even if patents are later invalidated.
• Merits wins can create durability for brand, especially if claims survive obviousness or written description attacks.

---

What settlement agreements change generic launch dates for EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE?

Featured snippet answer: Settlement agreements typically convert litigation uncertainty into a dated generic entry. The investor focus is the agreed first commercial marketing date for the relevant NDA strength(s).

What to model in revenue scenarios

• Entry date for:
  • Each strength
  • Each formulation variant if multiple presentations exist
• Whether entry is “authorized” (license-based) or “fully generic”
• Brand’s remaining exclusivity or co-pay programs after entry

Investment implication

• If settlements accelerate entry relative to nominal patent expiry, valuation must assume earlier pricing erosion.
• If settlements defer entry, brand cash flows can extend despite weaker underlying patent enforceability.

---

Is there biosimilar or biologics risk for EMTRICITABINE/RILPIVIRINE/TDF?

Featured snippet answer: No biosimilar risk typically applies. This combination is composed of small-molecule antiretrovirals and is generally addressed through ANDAs, not biosimilar pathways.

Investment implication

• Competition is driven by generic manufacturing scale and regulatory approval timing, not biosimilar interchangeability.

---

What formulations are protected for EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE (tablet strengths, dissolution, stability)?

Featured snippet answer: Formulation patents typically cover fixed-dose tablet manufacturing, dissolution profiles, stability under storage conditions, and sometimes specific excipient systems.

Why formulation patents matter in HIV fixed-dose combos

• Generic filers can sometimes satisfy bioequivalence yet still infringe formulation-specific dissolution or manufacturing claims.
• If a formulation patent is strong, it can delay FDA approval even when composition-of-matter is expired.

Investment implication

• A “narrow but enforceable” formulation moat can be more valuable than broad composition claims if it survives claim construction and invalidity arguments.

---

What method-of-use patents protect EMTRICITABINE/RILPIVIRINE/TDF dosing, patient selection, or timing?

Featured snippet answer: Method-of-use claims, when listed, can delay label-approved generic marketing because certification and design-around may not remove the protected regimen.

Common method-of-use claim patterns

• Treatment regimens with specific dose timing (including food instructions for NNRTI formulations).
• Patient subsets defined by prior therapy history or baseline characteristics.
• Combination or sequencing claims for HIV management.

Investment implication

• If method-of-use patents remain active, generic entry can still occur for unprotected dosing instructions or under a carved label, depending on claim scope and FDA label requirements.

---

How does EMTRICITABINE/RILPIVIRINE/TDF compare with competing HIV single-tablet regimens on patent and commercial durability?

Featured snippet answer: Comparable competitors in HIV fixed-dose markets often include other NNRTI- and INSTI-based regimens that may have newer patent estates and stronger guideline positioning.

Competitive durability drivers investors should test

• Guideline status and physician preference.
• Renal safety considerations for TDF-based regimens versus alternative tenofovir prodrugs in newer combos.
• Drug-drug interaction profile and tolerability.

Investment implication

• Even with patent protection, brand share can erode if prescribers move to newer regimens that are cheaper on net cost and easier to tolerate.

---

What generic entry risks exist for EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE after patent expiry?

Featured snippet answer: The primary risk is rapid market share loss after effective exclusivity ends, driven by multiple ANDAs and aggressive net pricing.

Entry risk checklist

• How many ANDAs are pending or launched for the same NDA strength.
• Whether approvals include “paragraph IV settlement” launch windows.
• Supply readiness of generic manufacturers.
• PBM and tender-driven switching timelines after first generic sale.

Investment implication

• If multiple entrants are ready, brand may see steep volume loss quickly rather than gradual erosion.

---

Which manufacturing or IP barriers could slow generic switching for EMTRICITABINE/RILPIVIRINE/TDF?

Featured snippet answer: Barriers are usually regulatory (bioequivalence, dissolution, stability data) and IP (formulation or process patents), rather than capacity constraints.

Practical barriers investors model

• Bioequivalence acceptance and dissolution matching.
• Litigation stays or ongoing appeals.
• Design-around changes that avoid formulation/process claim scope.

Investment implication

• Manufacturing constraints matter less than legal barriers once ANDA approval is available.

---

FDA status and regulatory pathway implications for investment in EMTRICITABINE/RILPIVIRINE/TDF

Featured snippet answer: Investment depends on NDA reference status and whether any supplemental approvals create new exclusivity blocks or new patent listings tied to specific strengths.

What to model in FDA records

• NDA approvals and supplement types (manufacturing changes, formulation changes, labeling).
• Whether new strength or dosage form approvals triggered new patent listings.
• Whether any changes shifted exclusivity or re-triggered listed patent coverage.

Investment implication

• New supplemental approvals can extend practical exclusivity if they are tied to fresh regulatory exclusivity or to new listed patents.

---

Geographic exposure: where is the exclusivity and generic risk highest for EMTRICITABINE/RILPIVIRINE/TDF?

Featured snippet answer: The highest risk markets are those with mature generic ecosystems and aggressive tendering, where patent enforcement is harder or slower relative to generic supply chains.

Geographic underwriting approach

• Model priority revenue countries and overlay:
  • Patent coverage strength (broad versus narrow)
  • Typical enforcement tempo
  • Tendering cycles that accelerate switching
  • Local authorized generic programs

Investment implication

• If key revenues sit in markets with quicker generic uptake, brand durability compresses even with remaining US patents.

---

Key Takeaways

• Investment value for EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL FUMARATE hinges on whether meaningful, active Orange Book-listed patents still cover the exact marketed strength(s) and dosage form(s).
• Generic entry is the core risk, driven by ANDA approvals, Paragraph IV litigation timing, and settlement-triggered launch dates.
• Formulation and method-of-use patents are the most plausible sources of residual barriers; composition-of-matter assets usually translate into shorter practical durability for combination ARVs.
• No biosimilar risk applies; competition is regulatory small-molecule generic competition.

---

FAQs

1. How do Orange Book “method of use” patents affect generic labeling for fixed-dose HIV combinations?
2. What does a 30-month Paragraph IV stay change in revenue forecasts for antiretroviral brands?
3. How often do HIV fixed-dose combinations see faster erosion due to guideline switches rather than patent expiry?
4. When formulation patents exist, what design-around strategies typically reduce infringement risk for ANDA filers?
5. Which factors most strongly predict whether generics enter simultaneously across strengths (single vs multiple approvals)?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
2. FDA. Drug Approval Reports / NDA/BLA information and labeling history for the relevant NDA. US FDA.
3. FDA. Paragraph IV Certification and 30-month stay framework. US FDA.